August 29, 2016 10:00 AM ET

Biotechnology

Company Overview of Nivalis Therapeutics, Inc.

Key Executives for Nivalis Therapeutics, Inc.

NameBoard RelationshipsTitleAge
Jon Congleton 12 RelationshipsChief Executive Officer, President and Director53
R. Michael Carruthers 14 RelationshipsChief Financial Officer and Secretary58
Janice M. Troha No RelationshipsChief Operating Officer and Executive Vice President58
David M. Rodman M.D.No RelationshipsChief Medical Officer and Executive Vice President of Discovery--

Nivalis Therapeutics, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
Howard P. Furst M.D. 17 RelationshipsDeerfield Management Company, L.P.49
Jon Congleton 12 RelationshipsNivalis Therapeutics, Inc.53
John R. Moore 12 RelationshipsArray BioPharma Inc.52
Robert E. Conway CPA 148 RelationshipsARCA biopharma, Inc.62
Michael A. Marletta Ph.D., M.D. 35 RelationshipsThe Scripps Research Institute65
View All Board Members

Nivalis Therapeutics, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee CPARobert E. Conway148 Relationships3 Executives
Compensation Committee John R. Moore12 Relationships3 Executives
Nominating Committee M.D.Howard P. Furst17 Relationships3 Executives
Corporate Governance Committee M.D.Howard P. Furst17 Relationships3 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.
 

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

CEO COMPENSATION IN THIS INDUSTRY

  Industry Range
Salary$375.0K
375.0K
379.6K
Bonus
Not meaningful
Total Short Term Compensation
Not meaningful
Total Value of Options$375.0K
375.0K
33.3M
Compensation as of Fiscal Year 2015
Nivalis Therapeutics, Inc. CEO Compensation
Industry Average

INDUSTRY EXECUTIVE CHANGES

ProclaRx Appoints Doug Martin as New Chief Operating Officer
August 27, 2016 7:45 AM ET
Juno Therapeutics, Inc. Announces Resignation of Marc Tessier-Lavigne from the Board of Directors
August 26, 2016 9:11 PM ET
Agios Pharmaceuticals, Inc. Announces Management Changes
August 26, 2016 8:02 PM ET
Tapimmune, Inc. Appoints Michael Loiacono as Chief Financial Officer, Chief Accounting Officer, Secretary and Treasurer
August 25, 2016 12:52 PM ET
OptiBiotix Health plc Announces Executive Changes
August 25, 2016 6:00 AM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Nivalis Therapeutics, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.